Evaluation and Monitoring the Medication of Critically Ill Patients with COVID-19 and Cerebral Hemorrhage during Convalescence

doi:10.19803/j.1672-8629.2020.04.04

Abstract

Abstract: Objective To evaluate and monitor the medication of one critically ill patient with cerebral hemorrhage during convalescence complicated with COVID-19, so as to privide reference for clinical drug safety. Methods The medication of one patient was analyzed in terms of pharmacodynamics, clinical pharmacology, monitoring and evaluation of adverse reactions, and the drug monitoring strategy was put forward. Results The medication of this patient was basically in line with the diagnosis and treatment of COVID-19. Conclusion The clinical manifestations of critically ill patients with COVID-19 and cerebral hemorrhage during convalescence are complex, so treatment plans should also take into consideration the convalescence related complications of intracerebral hemorrhage.

Key words: critically ill patient with COVID-19, cerebral hemorrhage during convalescence, pharmaceutical evaluation, pharmaceutical care

CLC Number:

R978.7

WANG Ying, ZHU Kun. Evaluation and Monitoring the Medication of Critically Ill Patients with COVID-19 and Cerebral Hemorrhage during Convalescence[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 208-213.

References

[1] Koren Gideon, King Susan, Knowles Sandra, et al.Ribavirin inthe treatment of SARS: A new trick for an old drug?[J]. CMAJ,2003, 168(10):1289-1292.
[2] Momattin H, Mohammed K, Zumla A, et al.Therapeutic optionsfor Middle EastRespiratory Syndrome Coronavirus (MERS-CoV)-possible lessons from asystematic review of SARS-CoV therapy[J].International Journal of Infectious Disease, 2013, 17(10): e792-e789.
[3] 田占红,王晨,郑然,等.磷酸奥司他韦联合抗病毒合剂对流感病毒感染患者的临床疗效[J/OL].中华医院感染学杂志,2020(2):288-291. [2020-02-22]. http://kns.cnki.net/kcms/detail/11.3456.r.20200113.2019.058.html.
[4] Matsuyama Ryota, Nishiura Hiroshi, Kutsuna Satoshi, et al.Clinical determinants of the severity of Middle East respiratorysyndrome (MERS): a systematic review and meta-analysis[J].BMC Public Health, 2016, 16(1):1203.
[5] 江华, 邓洪飞, 王宇, 等. 洛匹那韦/利托那韦(LPV/r)用于2019新型冠状病毒肺炎的治疗可能性:基于既往冠状病毒肺炎研究的快速系统评价[J]. 中华急诊医学杂志, 2020, 29(2):182-186.
[6] Huang Kao-Jean, Su Ih-Jen, Theron Michel, et al.An interferon-gamma-related cytokine storm in SARS patients[J]. J Med Virol,2005, 75(2):185-194.
[7] 陈岷,童荣生,边原,等.皮下注射α-干扰素治疗2019年新型冠状病毒的循证快速评估[J/OL].医药导报:1-19[2020-03-02].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.
[8] Bulgakova VA, Poromov AA, Grekova AI, et al.Pharmacoepide-miological study of the course of influenza and other acute respiratoryviral infections in risk groups[J]. Ter Arkh, 2017, 89(1): 62-71.
[9] Gregory PC, Kuhlemeier KV .Prevalence of Venous Thrombo-embolism in Acute emorrhagic and Thromboembolic Stroke[J].American Journal of Physical Medicine & Rehabilitation, 2003,82(5):364-369.
[10] van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, casefatality, and functional outcome of intracerebral haemorrhageover time, according to age, sex, and ethnic origin: a systematicreview and meta-analysis[J]. Lancet Neurology, 2010, 9(2):167-176.
[11] Hemphill J Claude, Greenberg Steven M, Anderson Craig S,et al.Guidelines for the Management of Spontaneous IntracerebralHemorrhage: A Guideline for Healthcare Professionals From theAmerican Heart Association/American Stroke Association[J].Stroke, 2015, 46(7):2032-2060.
[12] 徐佳强,曾芳,吴艳,等.新型冠状病毒感染肺炎重症患者的营养支持及监护建议[J/OL].中国医院药学杂志:1-3. [2020-02-22].http://kns.cnki.net/kcms/detail/42.1204.r.20200218.0954.002.html.
[13] 肖颖彬. 重视新型冠状病毒肺炎对心脏的损害[J].西部医学,2020, 32(3):313-315.
[14] 赵荣生,杨毅恒,杨丽,等. 新型冠状病毒防控的药学工作指导与管理策略[J/OL].中国药学杂志:1-31.[2020-02-22].http://kns.cnki.net/kcms/detail/11.2162.R.20200207.0936.002.html.
[15] 中华医学会临床药学分会《雾化吸入疗法合理用药专家共识》编写组. 雾化吸入疗法合理用药专家共识(2019年版)[J]. 医药导报, 2019, 38(2):135-146.
[16] 王丹丹,史长松.干扰素生物学作用及雾化治疗研究进展[J].现代临床医学, 2018, 44(6):474-476.
[17] Russell CD, Millar JE, Baillie JK.Clinical evidence does notsupport corticosteroid treatment for 2019-nCoV lung injury[J].Lancet, 2020, 395(10223):473-475.
[18] 《内科住院患者静脉血栓栓塞症预防的中国专家建议》写作组,中华医学会老年医学分会,中华医学会呼吸病学分会,等.内科住院患者静脉血栓栓塞症预防中国专家建议(2015)[J].中华老年医学杂志, 2015, 34(4):345-352.
[19] 刘子涵,郑恩来,张凤,等.血管紧张素转换酶2对心血管系统疾病影响的研究进展[J].中国老年学杂志, 2019, 39(6):1520-1522.
[20] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hos-pitalized Patients With2019 Novel Coronavirus-Infected Pneu-monia in Wuhan, China[J]. JAMA, 2020, in press. DOI: 10.1001/jama.2020.1585.